Siltuximab (INN[4]), sold under the brand name Sylvant, is used for the treatment of people with multicentric Castleman's disease.

[2] The common adverse reactions include pruritus, increased weight, rash, hyperuricemia, and upper respiratory tract infection.

[2][3] The common adverse reactions include pruritus, increased weight, rash, hyperuricemia, and upper respiratory tract infection.

[2] Siltuximab demonstrated efficacy and safety in people with idiopathic multicentric Castleman disease.

[7][8] Treatment results with siltuximab in B-cell non-Hodgkin's lymphoma are inferior to those obtained in multicentric Castleman disease.